Physician

Anthony F. Ognjan, D.O.

According to 2025 Medicare claims, Anthony Ognjan, D.O. (NPI: 1144278847) practices infectious disease in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Macomb, MI. This provider's primary affiliated billing organization is METRO INFECTIOUS DISEASE CONSULTANTS, LLC (NPI: 1235125717; TIN: 363966745) and primary practice location at 48314-1723. Ognjan is affiliated with the Mosaic ACO (ACO ID: A5033) and American Choice Healthcare, LLC (ACO ID: D0086), participating under both the MSSP and REACH models.

Ognjan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 269 traditional Medicare patients, billed 9,236 HCPCS/CPT codes, and received $168,501 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 294 prescription claims across 36 beneficiaries totaling $1,037,991 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). 2019 DME data shows 59 claims. Open Payments data shows 1 records totaling $125. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $237,510 to $168,501. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $29,468 and ending at $11,706.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	526	3,649	$237,510
2016	555	12,361	$351,040
2017	515	22,383	$318,515
2018	565	31,270	$647,432
2019	597	38,708	$547,904
2020	558	36,553	$551,950
2021	430	22,196	$603,248
2022	463	15,039	$257,148
2023	333	16,073	$265,906
2024	269	9,236	$168,501

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	92	891	$977,219
2016	90	852	$1,075,109
2017	81	756	$1,125,493
2018	102	802	$1,130,011
2019	114	835	$1,208,677
2020	105	734	$1,308,069
2021	72	523	$1,159,390
2022	69	441	$1,087,017
2023	39	319	$1,044,133
2024	36	294	$1,037,991

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	162	$22,507
2016	12	63	$7,238
2017	N/R	N/R	N/R
2018	N/R	26	$799
2019	N/R	59	$8,437
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	125	132	$134
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	25	26	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	110	176	$92
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	83	135	$62
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	22	25	$49

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	186	6,180	$819,408
Juluca	Dolutegravir/Rilpivirine	20	600	$72,220
Prezcobix	Darunavir/Cobicistat	20	600	$51,436
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	12	360	$46,938
Isentress	Raltegravir Potassium	11	330	$21,214

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$125	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony F. Ognjan, D.O.?

Tedicare shows public-source Medicare data for Anthony F. Ognjan, D.O. (NPI 1144278847), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony F. Ognjan, D.O. have ACO affiliation data?

Anthony F. Ognjan, D.O. is shown with ACO affiliation data for Mosaic ACO (MSSP, ACO ID A5033) and American Choice Healthcare, LLC (REACH, ACO ID D0086).

What billing organization is linked to Anthony F. Ognjan, D.O.?

Anthony F. Ognjan, D.O. is linked to METRO INFECTIOUS DISEASE CONSULTANTS, LLC (billing NPI 1235125717) in the available physician profile data.

Does Anthony F. Ognjan, D.O. have Open Payments data?

Anthony F. Ognjan, D.O. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.